EOP2A Guidance Allows That Resource Constraints Might Block Meetings
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA's final guidance on end-of-Phase 2A meetings codifies into policy the more realistic expectations of what the agency can handle in terms of meeting requests.